GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Change In Payables And Accrued Expense

Ipsen (IPSEY) Change In Payables And Accrued Expense : $0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Ipsen Change In Payables And Accrued Expense?

Ipsen's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $0 Mil. It means Ipsen's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Ipsen's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0 Mil. It means Ipsen's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Ipsen Change In Payables And Accrued Expense Historical Data

The historical data trend for Ipsen's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Change In Payables And Accrued Expense Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ipsen Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ipsen Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Ipsen's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (IPSEY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB BOM:532321 TSE:4507 HKSE:03692 VTRS
Traded in Other Exchanges
IPSEF:USA 0MH6:UK IPN:France I7G:Germany
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.